Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL).
Elias Jabbour
No relevant relationships to disclose
Susan Mary O'Brien
No relevant relationships to disclose
Nitin Jain
No relevant relationships to disclose
Deborah A. Thomas
No relevant relationships to disclose
Guillermo Garcia-Manero
No relevant relationships to disclose
Farhad Ravandi
No relevant relationships to disclose
Gautam Borthakur
No relevant relationships to disclose
Sergernne York
No relevant relationships to disclose
Rebecca Garris
No relevant relationships to disclose
Jorge E. Cortes
No relevant relationships to disclose
Hagop M. Kantarjian
Research Funding - Pfizer